Table 4

IFN-γ T-cell responses, autoimmune toxicities and clinical outcomes by patient and in aggregate

PatientStudy armVaccine with:T-cell response detected to:Baseline* ANA/RF+On-treatment
ANA+
Melanoma clinical outcome October 2019
pBCAR3pIRS2pBCAR3pIRS2EitherRecurrenceDied
1A++++
2A+
3B+++
4A+++++
5B+++++
6B++
7C+++
8C++++++
9C+++
10C++++
11C+++++
12C++
13C++++++
14C++
15C+++++
Total121225633103
# vaccinated with that peptide121215
% T-cell response to peptide17%42%40%
90% CI T-cell responses3% to 44%18% to 68%19% to 64%
  • ANA, antinuclear antibody; IFN-γ, interferon-γ; pBCAR3, phosphopeptide from breast cancer antiestrogen resistance 3; pIRS2, phosphopeptide from insulin receptor substrate 2; RF, rheumatoid factor.